Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

14. Februar 2017 16:12 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Announces Record Date for the 2017 Annual Meeting of Stockholders

CARMIEL, Israel, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that its board of directors approved the record date for the Company’s...
13. Februar 2017 07:00 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics to Participate in the 13th Annual WORLDSymposium™ 2017

Data to be presented in three oral presentations and two poster presentations CARMIEL, Israel, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced...
09. Januar 2017 06:00 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Provides Review of 2016 and Strategic Outlook for 2017

Full Switch Plan Initiated and Published by Brazilian Ministry of Health for Gaucher Patients in Brazil Yielding Significant Revenue Stream Fabry Phase III Clinical Trial Underway with Interim...
03. Januar 2017 07:30 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Announces Positive Interim Results from Phase II Clinical Trial of alidornase alfa (AIR DNase™) for the Treatment of Cystic Fibrosis

CARMIEL, Israel, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today positive interim results from the Company’s phase II clinical trial of...
27. Dezember 2016 07:30 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Receives Confirmation of Order for over $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil

CARMIEL, Israel, Dec. 27, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) (the “Company”) announced today the confirmation of the recent letter of intent to...
22. Dezember 2016 07:30 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Announces Last Patient Enrolled in the AIR DNase™ Phase II Clinical Trial for Cystic Fibrosis

CARMIEL, Israel, Dec. 22, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the last patient has been enrolled in the Company’s phase II...
14. Dezember 2016 07:30 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Receives Letter Detailing Intended Purchases of Approximately $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil

CARMIEL, Israel, Dec. 14, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) (the “Company”) announced today that the Company received a letter from Fundação Oswaldo...
01. Dezember 2016 17:00 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Announces Investor Call

CARMIEL, Israel, Dec. 01, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) announced today that the Company will hold an investor conference call on December 2, 2016...
01. Dezember 2016 16:44 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Announces Private Note Exchanges and Private Placement of Secured Convertible Notes due 2021

CARMIEL, Israel, Dec. 01, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) (the “Company”) announced today the entry into a definitive exchange agreement relating to...
30. November 2016 07:30 ET | Quelle: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Enrolls First Patient in Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis

CARMIEL, Israel, Nov. 30, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the first patient has been enrolled in its phase II clinical trial...

Vorherige Seite